Jubilant Pharmova
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Jubilant Pharmova's recent strategic initiatives, particularly its Vision 2030 roadmap, underscore a commitment to expanding its high-margin segments, notably in sterile injectables and radiopharmaceuticals. Management's focus on enhancing production capabilities, such as the Spokane Line 4 expansion, is expected to drive revenue growth, despite current challenges from FDA compliance issues at the Montreal facility. Vista's financial outlook anticipates moderate revenue growth and margin pressures, reflecting the company's ongoing transition towards complex manufacturing. The anticipated launch of new products and operational stabilization are expected to improve EBITDA margins in the latter half of FY27. However, geopolitical uncertainties and raw material supply constraints remain critical watchpoints. Overall, while the long-term growth trajectory appears promising, short-term execution risks could hinder performance. Key opportunities include the expansion of the CDMO segment and strategic partnerships, while headwinds consist of regulatory challenges, competitive pricing pressures, and potential disruptions in supply chains
Why We Like This Stock
- Expansion of sterile injectables and radiopharmaceuticals is expected to drive revenue growth
- Strategic partnerships and new product launches provide strong pipeline visibility
- Management's focus on high-margin complex manufacturing aligns with industry trends
Things To Watch Out For
- FDA compliance issues at the Montreal facility pose execution risks
- Margin pressures are anticipated due to competitive pricing in legacy segments
- Geopolitical uncertainties and raw material supply constraints could disrupt operations
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 6,703 | 7,234 | 8,280 | 8,710 | 9,660 |
| Profit Before Tax (Cr.) | 339 | 621 | 673 | 612 | 705 |
| PBT Margin | 5.1% | 8.6% | 8.1% | 7.0% | 7.3% |
| Net Profit (Cr.) | -64 | 486 | 492 | 453 | 522 |
| Earnings Per Share | -3.8 | 31.0 | 31.2 | 28.6 | 33.0 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of pulmonary embolism, cancer, coronary artery disease, and other diseases. Its Allergy Immunotherapy segment provides specialized diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacture, distribution, sale, and marketing of generic formulations for therapeutic areas, such as cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment provides drug discovery services and active pharmaceutical ingredients. Its Proprietary Novel Drugs segment offers patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organizations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.